

Dear Examiner SQUIRES -

Below are results from the search you requested on application 10/814852.

The results are in our regular format, which begins with a search of both patent (mostly foreign) and general non-patent literature for the inventors' own works, and then proceeds to results which constitute prior art and subject-matter which were found in the same sets of literature.

For ease of use, results that appear of most direct relevance are highlighted in yellow and red.

Further, those highlighted results are also marked with a double tilde (~~) so that if you use the "Find" function under the Edit menu of Word, you can search for ~~ and you will be taken right to those selected results.

Also highlighted below is/are relevant material that may fall past the priority date of interest but may be close enough in time and art subject-matter that I call it to your attention.

But please examine all results, and those that may also accompany this set (if any), since the highlighting is merely a set of suggestions simply to aid a necessary review of the full results.

Matthew Hogan
Technical Information Specialist
EIC 3600 -- Knox 4B71
ASRC Management Services
USPTO Contractor
x26674
matthew.hogan@uspto.gov

Patent Literature – Inventor Searches

[File 348] EUROPEAN PATENTS 1978-200836
(c) 2008 European Patent Office. All rights reserved.

[File 349] PCT FULLTEXT 1979-2008/UB=20080904/UT=20080828
(c) 2008 WIPO/Thomson. All rights reserved.

[File 347] JAPIO Dec 1976-2007/Dec(Updated 080328)
(c) 2008 JPO & JAPIO. All rights reserved.

[File 350] Derwent WPIX 1963-2008/UD=200845
(c) 2008 The Thomson Corporation. All rights reserved.

Set	Items	Description
S1	23	S AU=(FAVA, M? OR FAVA M?)
S2	46	S AU=(SCHOENFELD, D? OR SCHOENFELD D?)
S3	0	S S1 AND S2
S4	69	S S1 OR S2
S5	12	S S4 AND (CLINIC? OR MEDIC? OR HEALTH OR PLACEBO)

RESULTS: Patent Literature – Inventor Searches

5/3,K/11 (Item 1 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0017805858

WPI Acc no: 2008-G26314/200839

XRAM Acc no: C2008-199753

XRPX Acc No: N2008-489193

Assessing prognosis of a patient by measuring the expression level of RNA species in a biological sample obtained from the patient and determining a comparative value for each RNA species

Patent Assignee: GEN HOSPITAL CORP (GEOH)

Inventor: ELSON C M; HAYDEN D; SCHOENFELD D; TOMPKINS R G; WARREN S H

Patent Family (1 patents, 120 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2008063521	A2	20080529	WO 2007US23917	A	20071113	200839	B

Original Titles:GENE-BASED CLINICAL SCORING SYSTEM... ..Inventor:

SCHOENFELD D Alerting Abstract ... tangibly embodied on a computer readable medium, containing instructions for controlling a system for predicting clinical outcome of a patient... Technology Focus ...tangibly embodied on a computer readable medium, containing instructions for controlling a system for predicting clinical outcome of a patient comprises: (a) means for determining a comparative value for each RNA...each patient. The means for prioritizing treatment also determines treatment priority based on the particular medical condition of the patient. The means for prioritizing treatment also determines treatment priority based on the severity of the medical condition of the patient. A patient with a higher score is assigned treatment priority in... ..score. The means for assigning a treatment priority category is also based on the particular medical condition of the patient. The means for assigning a treatment priority category determines treatment priority based on the severity of the medical condition of the patient. Extension Abstract Original Publication Data by AuthorityArgentinaPublication No. ...Inventor name & address:SCHOENFELD, David Original Abstracts:Systems and methods comprising microarray systems to assess prognostic potential in a clinical setting are described...

5/3K/6 (Item 1 from file: 349) [Links](#)

Fulltext available through: [Order File History](#)

PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

01668326

GENE-BASED CLINICAL SCORING SYSTEM

SYSTEME D'EVALUATION CLINIQUE BASE SUR DES GENES
GENE-BASED CLINICAL SCORING SYSTEM

Patent Applicant/Patent Assignee:

- THE GENERAL HOSPITAL CORPORATION; 55 Fruit Street, Boston, MA 02114
US; US (Residence); US (Nationality)
(For all designated states except: US)
- ELSON Constance M; 134 River Road, Winthrop, MA 02152
US; US (Residence); US (Nationality)
(Designated only for: US)
- HAYDEN Douglas; 153 River Street, Cambridge, MA 02139
US; US (Residence); US (Nationality)
(Designated only for: US)
- SCHOENFELD David; 41 Brook Road, Sharon, MA 02067
US; US (Residence); US (Nationality)
(Designated only for: US)
- WARREN Shaw Howland; 40 Royal Avenue, Cambridge, MA 02138
US; US (Residence); US (Nationality)
(Designated only for: US)
- TOMPKINS Ronald G; 2 Hawthorne Place, #8n, Boston, MA 02114
US; US (Residence); US (Nationality)
(Designated only for: US)
- ...Designated only for: US);
;;
- SCHOENFELD David... ;
;;

Patent Applicant/Inventor:

- ELSON Constance M
134 River Road, Winthrop, MA 02152; US; US (Residence); US (Nationality);
(Designated only for: US)
- HAYDEN Douglas
153 River Street, Cambridge, MA 02139; US; US (Residence); US (Nationality);
(Designated only for: US)
- SCHOENFELD David
41 Brook Road, Sharon, MA 02067; US; US (Residence); US (Nationality);
(Designated only for: US)
- WARREN Shaw Howland
40 Royal Avenue, Cambridge, MA 02138; US; US (Residence); US (Nationality);
(Designated only for: US)

- TOMPKINS Ronald G
2 Hawthorne Place, #8n, Boston, MA 02114; US; US (Residence); US (Nationality);
(Designated only for: US)

- ...Designated only for: US)

;;;;

- SCHOENFELD David...

;;;;

Legal Representative:

- LAURO Peter C et al(agent)

Edwards Angell Palmer & Dodge Llp, P.o. Box 55874, Boston, MA 02205; US;

	Country	Number	Kind	Date
Patent	WO	200863521	A2	20080529
Application	WO	2007US23917		20071113
Priorities	US	2006858617		20061113

Claims:

...tangibly embodied on a computer readable medium, containing instructions for controlling a system for predicting clinical outcome of a patient comprising: a) means for determining a comparative value for each of... ..51, wherein the means for prioritizing treatment also determines treatment priority based on the particular medical condition of the patient.

53. The machine readable program of claim 52, wherein the means for prioritizing treatment also determines treatment priority based on the severity of the medical condition of the patient.

54. The machine readable program of claim 53, wherein a patient... ..wherein the means for assigning a treatment priority category is also based on the particular medical condition of the patient.

60. The machine readable program of claim 51, wherein the means for assigning a treatment priority category determines treatment priority based on the severity of the medical condition of the patient.

5/3K/1 (Item 1 from file: 348) [Links](#)

Fulltext available through: [Order File History](#)

EUROPEAN PATENTS

(c) 2008 European Patent Office. All rights reserved.

02511035

GENE-BASED CLINICAL SCORING SYSTEM

SYSTEME D'EVALUATION CLINIQUE BASE SUR DES GENES

GENE-BASED CLINICAL SCORING SYSTEM

Patent Assignee:

- The General Hospital Corporation; (8076760)
55 Fruit Street; Boston, MA 02114; (US)
(Applicant designated States: all)

Inventor:

- ELSON, Constance M.
134 River Road; Winthrop, MA 02152; (US)
- HAYDEN, Douglas
153 River Street; Cambridge, MA 02139; (US)
- SCHOENFELD, David
41 Brook Road; Sharon, MA 02067; (US)
- WARREN, Shaw Howland
40 Royal Avenue; Cambridge, MA 02138; (US)
- TOMPKINS, Ronald G.
2 Hawthorne Place, 8n; Boston, MA 02114; (US)
- ...US)
;;
- SCHOENFELD, David...
;;

	Country	Number	Kind	Date
	WO	2008063521		20080529
Application	EP	2007862020		20071113
	WO	2007US23917		20071113
Priorities	US	858617	P	20061113

?

NON-Patent Literature – Full Text – Inventor Search

[File 149] TGG Health&Wellness DB(SM) 1976-2008/Sep W1
(c) 2008 Gale/Cengage. All rights reserved.

[File 444] New England Journal of Med. 1985-2008/Jun W4
(c) 2008 Mass. Med. Soc. All rights reserved.

[File 455] Drug News & Perspectives 1992-2005/Aug
(c) 2005 Prous Science. All rights reserved.

**File 455: This file is closed. Please see HELP NEWS 455 for more information.*

[File 129] PHIND(Archival) 1980-2008/Aug W4
(c) 2008 Informa UK Ltd. All rights reserved.

[File 130] PHIND(Daily & Current) 2008/Oct 02
(c) 2008 Informa UK Ltd. All rights reserved.

[File 15] ABI/Inform(R) 1971-2008/Oct 02
(c) 2008 ProQuest Info&Learning. All rights reserved.

[File 9] Business & Industry(R) Jul/1994-2008/Sep 25
(c) 2008 Gale/Cengage. All rights reserved.

[File 610] Business Wire 1999-2008/Oct 02
(c) 2008 Business Wire. All rights reserved.

**File 610: File 610 now contains data from 3/99 forward. Archive data (1986-2/99) is available in File 810.*

[File 810] Business Wire 1986-1999/Feb 28
(c) 1999 Business Wire . All rights reserved.

[File 275] Gale Group Computer DB(TM) 1983-2008/Sep 22
(c) 2008 Gale/Cengage. All rights reserved.

[File 995] NewsRoom 2004
(c) 2008 Dialog. All rights reserved.

[File 996] NewsRoom 2000-2003
(c) 2008 Dialog. All rights reserved.

[File 624] McGraw-Hill Publications 1985-2008/Oct 02
(c) 2008 McGraw-Hill Co. Inc. All rights reserved.

**File 624: Journal updates now current*

[File 621] Gale Group New Prod.Annou.(R) 1985-2008/Sep 10
(c) 2008 Gale/Cengage. All rights reserved.

[File 636] Gale Group Newsletter DB(TM) 1987-2008/Sep 23
(c) 2008 Gale/Cengage. All rights reserved.

[File 613] PR Newswire 1999-2008/Oct 02
(c) 2008 PR Newswire Association Inc. All rights reserved.

[File 813] PR Newswire 1987-1999/Apr 30
(c) 1999 PR Newswire Association Inc. All rights reserved.

[File 16] Gale Group PROMT(R) 1990-2008/Sep 24
(c) 2008 Gale/Cengage. All rights reserved.

**File 16: Because of updating irregularities, the banner and the update (UD=) may vary.*

[File 160] Gale Group PROMT(R) 1972-1989
(c) 1999 The Gale Group. All rights reserved.

[File 634] San Jose Mercury Jun 1985-2008/Sep 30
(c) 2008 San Jose Mercury News. All rights reserved.

[File 148] Gale Group Trade & Industry DB 1976-2008/Sep 29
(c) 2008 Gale/Cengage. All rights reserved.

**File 148: The CURRENT feature is not working in File 148. See HELP NEWS148.*

[File 20] Dialog Global Reporter 1997-2008/Oct 02
(c) 2008 Dialog. All rights reserved.

Set	Items	Description
S1	64	S AU=(FAVA, M? OR FAVA M?)
S2	41	S AU=(SCHOENFELD, D? OR SCHOENFELD D?)
S3	0	S S1 AND S2
S4	105	S S1 OR S2
S5	1	S S4 AND (PLACEBO())EFFECT?)

RESULTS: NON-Patent Literature – Full Text – Inventor Search

5/3,K/1 (Item 1 from file: 148) [Links](#)

Gale Group Trade & Industry DB

(c) 2008 Gale/Cengage. All rights reserved.

09840340 Supplier Number: 19768037 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Random-effects model for multiple characteristics with possibly missing data.

Shah, Amrik; Laird, Nan; Schoenfeld, David

Journal of the American Statistical Association , v92 , n438 , p775(5)

June , 1997

ISSN: 0162-1459

Language: English

Record Type: Fulltext; Abstract

Word Count: 3790 Line Count: 00332

...Schoenfeld, David

...Omitted)

and

(Mathematical Expression Omitted).

Table 1. Fixed-Effects Estimates

Treatment	ML		REML	
	Treatment			
Parameter	Placebo	effect	Placebo	
effect				
(Int.sub. (cd4))	3.6895	-.1525	3.6896	-.1524
(Slope.sub. (cd4))	-.0164	.0035	-.0164...	

NON-Patent Literature – Non Full Text – Inventor Search

[File 35] Dissertation Abs Online 1861-2008/Sep
(c) 2008 ProQuest Info&Learning. All rights reserved.

**File 35: UD names adjusted; All data present.*

[File 583] Gale Group Globalbase(TM) 1986-2002/Dec 13
(c) 2002 Gale/Cengage. All rights reserved.

**File 583: This file is no longer updating as of 12-13-2002.*

[File 65] Inside Conferences 1993-2008/Oct 01
(c) 2008 BL.DSC all rts. reserv. All rights reserved.

[File 2] INSPEC 1898-2008/Aug W5
(c) 2008 Institution of Electrical Engineers. All rights reserved.

[File 474] New York Times Abs 1969-2008/Oct 02
(c) 2008 The New York Times. All rights reserved.

[File 475] Wall Street Journal Abs 1973-2008/Oct 02
(c) 2008 The New York Times. All rights reserved.

[File 99] Wilson Appl. Sci & Tech Abs 1983-2008/Aug
(c) 2008 The HW Wilson Co. All rights reserved.

[File 5] Biosis Previews(R) 1926-2008/Sep W4
(c) 2008 The Thomson Corporation. All rights reserved.

[File 73] EMBASE 1974-2008/Oct 01
(c) 2008 Elsevier B.V. All rights reserved.

[File 155] MEDLINE(R) 1950-2008/Sep 29
(c) format only 2008 Dialog. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2008/Sep W4
(c) 2008 The Thomson Corp. All rights reserved.

[File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 2006 The Thomson Corp. All rights reserved.

Set	Items	Description
S1	1925	S AU=(FAVA, M? OR FAVA M?)
S2	1051	S AU=(SCHOENFELD, D? OR SCHOENFELD D?)
S3	10	S S1 AND S2
S4	2956	S (S1 OR S2) NOT S3
S5	3	S S4 AND (PLACEBO()EFFECT?)

[File 74] Int.Pharm.Abs 1970-2008/Aug B1
(c) 2008 The Thomson Corporation. All rights reserved.

[File 42] Pharm. News Index 1974-2008/Sep W1
(c) 2008 ProQuest Info&Learning. All rights reserved.

Set	Items	Description
S1	50	S AU=(FAVA, M? OR FAVA M?)
S2	2	S AU=(SCHOENFELD, D? OR SCHOENFELD D?)
S3	0	S S1 AND S2
S4	0	S S1 AND PLACEBO()EFFECT?

RESULTS: NON-Patent Literature – Non Full Text – Inventor

3/3,K/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

17357776 Biosis No.: 200300316495

The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach.

Author: Fava Maurizio (Reprint); Evins A Eden; Dorer David J; Schoenfeld David A
Author Address: Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St., WACC-812, Boston, MA, 02114, USA** USA

Author E-mail Address: MFava@partners.org

Journal: Psychotherapy and Psychosomatics 72 (3): p 115-127 May-June 2003 2003

Medium: print

ISSN: 0033-3190 _(ISSN print)

Document Type: Article; Literature Review

Record Type: Abstract

Language: English

Author: Fava Maurizio... ..Schoenfeld David A

3/3,K/2 (Item 2 from file: 5) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2008 The Thomson Corporation. All rights reserved.

16159248 Biosis No.: 200100331087

Tryptophan depletion in SSRI-recovered depressed outpatients

Author: Spillmann Maya K; Van der Does A J Willem; Rankin Meridith A; Vuolo Rachel D; Alpert Jonathan E; Nierenberg Andrew A; Rosenbaum Jerrold F; Hayden Douglas; Schoenfeld David; Fava Maurizio (Reprint)

Author Address: Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA, 02114, USA**USA

Journal: Psychopharmacology 155 (2): p 123-127 May, 2001 2001

Medium: print

ISSN: 0033-3158

Document Type: Article

Record Type: Abstract

Language: English

Author: ...Schoenfeld David... ..Fava Maurizio

3/3,K/3 (Item 1 from file: 73) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.
0079897739 EMBASE No: 2004082637

Erratum: The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach (Psychotherapy and Psychosomatics (2003) 72:3 (115-127))

Fava M.; Evins A.E.; Dorer D.J.; Schoenfeld D.A.

Psychotherapy and Psychosomatics (Psychother. Psychosom.) (Switzerland) March 3, 2004 , 73/2 (123)

CODEN: PSPSB ISSN: 0033-3190

Item Identifier (DOI): [10.1159/000076725](https://doi.org/10.1159/000076725)

Document Type: Journal ; Erratum Record Type: Citation

Language: English

Fava M... ..Schoenfeld D.A.

3/3,K/4 (Item 2 from file: 73) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)
EMBASE

(c) 2008 Elsevier B.V. All rights reserved.
0079462188 EMBASE No: 2003167337

The problem of the placebo response in clinical trials for psychiatric disorders: Culprits, possible remedies, and a novel study design approach

Fava M.; Evins A.E.; Dorer D.J.; Schoenfeld D.A.

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Harvard Medical School, Psychiatry for Clinical Research, Massachusetts General Hospital, 15 Parkman St., Boston, MA 02114, United States

Author email: MFava@partners.org

Corresp. Author/Affil: Fava M.: Harvard Medical School, Psychiatry for Clinical Research, Massachusetts General Hospital, 15 Parkman St., Boston, MA 02114, United States

Corresp. Author Email: MFava@partners.org

Psychotherapy and Psychosomatics (Psychother. Psychosom.) (Switzerland) May 8, 2003 , 72/3 (115-127)

CODEN: PSPSB ISSN: 0033-3190

Item Identifier (DOI): [10.1159/000069738](https://doi.org/10.1159/000069738)

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 38

Fava M... ..Schoenfeld D.A.

Corresp. Author/Affil: Fava M.: Harvard Medical School, Psychiatry for Clinical Research, Massachusetts General Hospital, 15 Parkman St., Boston...

Corresp. Author Email:

3/3,K/5 (Item 3 from file: 73) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0078563982 EMBASE No: 2001170123

Tryptophan depletion in SSRI-recovered depressed outpatients

Spillmann M.K.; Van der Does A.J.W.; Rankin M.A.; Vuolo R.D.; Alpert J.E.; Nierenberg A.A.; Rosenbaum J.F.; Hayden D.; Schoenfeld D.; Fava M.

Depression Clin. and Res. Program, Massachusetts Gen. Hosp., WAC 812, 15 Parkman Street, Boston, MA 02114, United States

Corresp. Author/Affil: Fava M.: Depression Clin. and Res. Program, Massachusetts Gen. Hosp., WAC 812, 15 Parkman Street, Boston, MA 02114, United States

Corresp. Author Email: Mfava@partners.org

Psychopharmacology (Psychopharmacology) (Germany) June 9, 2001 , 155/2 (123-127)

CODEN: PSCHID ISSN: 0033-3158

Item Identifier (DOI): [10.1007/s002130000669](#)

Document Type: Journal ; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 21

...Schoenfeld D... ..Fava M.

Corresp. Author/Affil: Fava M.: Depression Clin. and Res. Program, Massachusetts Gen. Hosp., WAC 812, 15 Parkman Street, Boston...

Corresp. Author Email:

3/3,K/6 (Item 1 from file: 155) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

15150570 PMID: 12707478

The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach.

Fava Maurizio; Evins A Eden; Dorer David J; Schoenfeld David A

Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. MFava@partners.org

Psychotherapy and psychosomatics (Switzerland) May-Jun 2003 , 72 (3) p115-27 , ISSN: 0033-3190--Print Journal Code: 0024046

Publishing Model Print; Erratum in Psychother Psychosom. 2004 Mar-Apr;73(2) 123

Document type: Journal Article; Research Support, Non-U.S. Gov't; Review

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Fava Maurizio; Evins A Eden; Dorer David J; Schoenfeld David A

3/3,K/7 (Item 2 from file: 155) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

14125993 PMID: 11400999

Tryptophan depletion in SSRI-recovered depressed outpatients.

Spillmann M K; Van der Does A J; Rankin M A; Vuolo R D; Alpert J E; Nierenberg A A; Rosenbaum J F; Hayden D; Schoenfeld D; Fava M
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA.

Psychopharmacology (Germany) May 2001 , 155 (2) p123-7 , ISSN: 0033-3158--Print
Journal Code: 7608025

Contract/Grant No.: M01-RR0-1066; RR; United States NCRR

Publishing Model Print

Document type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...A; Vuolo R D; Alpert J E; Nierenberg A A; Rosenbaum J F; Hayden D; Schoenfeld D; Fava M

3/3,K/8 (Item 1 from file: 34) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

12493282 Genuine Article#: 771HK No. References: 1

The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach (vol 72, pg 115, 2003)

Author: Fava M; Evins AE; Dorer DJ; Schoenfeld DA

Journal: PSYCHOTHERAPY AND PSYCHOSOMATICS , 2004 , V 73 , N2 , P 123-123

ISSN: 0033-3190 Publication date: 20040000

Publisher: KARGER , ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND

Language: English Document Type: CORRECTION

Author: Fava M; Evins AE; Dorer DJ; Schoenfeld DA

3/3,K/9 (Item 2 from file: 34) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

11651029 Genuine Article#: 678FK No. References: 37

The problem of the placebo response in clinical trials for psychiatric disorders:

Culprits, possible remedies, and a novel study design approach

Author: Fava M (REPRINT) ; Evins AE; Dorer DJ; Schoenfeld DA

Corporate Source: Harvard Univ,Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Depress Clin & Res Program,WACC-812,15 Parkman St/Boston//MA/02114 (REPRINT); Harvard Univ,Massachusetts Gen Hosp, Sch Med, Dept Psychiat,Depress Clin & Res Program,Boston//MA/02114; Harvard Univ,Massachusetts Gen Hosp, Sch Med, Ctr Biostat,Boston//MA/02114
Journal: PSYCHOTHERAPY AND PSYCHOSOMATICS , 2003 , V 72 , N3 (MAY-JUN) , P 115-127
ISSN: 0033-3190 Publication date: 20030500
Publisher: KARGER , ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Author: Fava M (REPRINT) ; Evins AE; Dorer DJ; Schoenfeld DA

3/3,K/10 (Item 3 from file: 34) [Links](#)
Fulltext available through: [STIC Full Text Retrieval Options](#)
SciSearch(R) Cited Ref Sci
(c) 2008 The Thomson Corp. All rights reserved.
09675842 Genuine Article#: 433UK No. References: 21
Tryptophan depletion in SSRI-recovered depressed outpatients

Author: Spillmann MK; Van der Does AJW; Rankin MA; Vuolo RD; Alpert JE; Nierenberg AA; Rosenbaum JF; Hayden D; Schoenfeld D; Fava M (REPRINT)
Corporate Source: Massachusetts Gen Hosp,Depress Clin & Res Program, WAC 812,15 Parkman St/Boston//MA/02114 (REPRINT); Massachusetts Gen Hosp,Depress Clin & Res Program, WAC 812,Boston//MA/02114; Leiden Univ,Dept Psychol,Leiden//Netherlands; Leiden Univ,Dept Psychiat,Leiden//Netherlands/
Journal: PSYCHOPHARMACOLOGY , 2001 , V 155 , N2 (MAY) , P 123-127
ISSN: 0033-3158 Publication date: 20010500
Publisher: SPRINGER-VERLAG , 175 FIFTH AVE, NEW YORK, NY 10010 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Author: ...der Does AJW; Rankin MA; Vuolo RD; Alpert JE; Nierenberg AA; Rosenbaum JF; Hayden D; Schoenfeld D; Fava M (REPRINT)

5/3,K/1 (Item 1 from file: 155) [Links](#)
Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)
(c) format only 2008 Dialog. All rights reserved.
17097859 PMID: 16783809
Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.

Farabaugh Amy H; Sonawalla Shamsah B; Fava Maurizio; Pedrelli Paola; Papakostas George I; Schwartz Faye; Mischoulon David
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA. afarabaugh@partners.org USA.
Human psychopharmacology (England) Jun 2006 , 21 (4) p221-5 , ISSN: 0885-6222--
Print Journal Code: 8702539

Publishing Model Print
Document type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Farabaugh Amy H; Sonawalla Shamsah B; Fava Maurizio; Pedrelli Paola; Papakostas George I; Schwartz Faye; Mischoulon David
Descriptors: *Cognition--drug effects--DE; *Depressive Disorder, Major--drug therapy--DT ; *Fluoxetine--therapeutic use--TU; *Placebo Effect

5/3,K/2 (Item 2 from file: 155) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

16837156 PMID: 16415707

A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.

Papakostas George I; Perlis Roy H; Scalia Margaret J; Petersen Timothy J; Fava Maurizio
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. gpapakostas@partners.org
Journal of clinical psychopharmacology (United States) Feb 2006 , 26 (1) p56-60 , ISSN: 0271-0749--Print Journal Code: 8109496

Contract/Grant No.: K23 MH069629; MH; United States NIMH

Publishing Model Print; Comment in Evid Based Ment Health. 2006 Aug;9(3) 78 ; Comment in PMID 16868197

Document type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Papakostas George I; Perlis Roy H; Scalia Margaret J; Petersen Timothy J; Fava Maurizio
Descriptors: ; Humans; Placebo Effect; Randomized Controlled Trials as Topic ; Time Factors

Named Person:

5/3,K/3 (Item 3 from file: 155) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)
MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

12635834 PMID: 9554429

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.

Stewart J W; Quitkin F M; McGrath P J; Amsterdam J; Fava M; Fawcett J; Reimherr F; Rosenbaum J; Beasley C; Roback P

Department of Psychiatry, New York State Psychiatric Institute, New York, USA.

Archives of general psychiatry (UNITED STATES) Apr 1998 , 55 (4) p334-43 , ISSN:

0003-990X--Print Journal Code: 0372435

Publishing Model Print

Document type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Stewart J W; Quitkin F M; McGrath P J; Amsterdam J; Fava M; Fawcett J; Reimherr F;

Rosenbaum J; Beasley C; Roback P

Descriptors: ; ...diagnosis--DI; Depressive Disorder--psychology--PX; Double-Blind Method ; Humans; Middle Aged; Pattern Recognition, Automated; Placebo Effect; Placebos; Probability; Prognosis; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome

Named Person:

Patent Literature – Non Full Text Subject Searches

[File 347] JAPIO Dec 1976-2007/Dec(Updated 080328)

(c) 2008 JPO & JAPIO. All rights reserved.

[File 350] Derwent WPIX 1963-2008/UD=200862

(c) 2008 Thomson Reuters. All rights reserved.

Set	Items	Description
S1	185821	S (FORMULA? ? OR ALGORITHM? ? OR SYSTEM? ? OR METHODOLOGY OR FUNCTION? ? OR EQUATION? ? OR (STATISTIC? OR PROBABIL? OR MATHEMATIC?))METHOD? ?) (4N) (EFFECT? OR EFFICAC? OR USEFULNESS OR UTILITY OR RESPON???? OR RESULTS OR OUTCOME?)
S2	165	S (REDUC? OR DIMIN? OR MITIGAT? OR TAK?)ACCOUNT OR ELIMIN? OR (ALLOW? OR CONTROL?) (FOR OR BIAS? OR UNBIAS? OR SCREEN? OR FILTER?) (4N) (PLACEBO? OR (INACTIVE OR INERT OR FALSE OR DUMMY OR FAKE)) (SUBSTANCE OR DRUG OR TREATMENT OR PHARMACEUTICAL?) OR SUGAR()PILL? OR PSYCHOSOMATIC)
S3	1599	S (ELIMIN? OR DISQUAL? OR SCREEN? OR FILTER? OR REMOV? OR RID OR RIDDING OR DROP OR DROPS OR DROPP???) (4N) (NONRESPON? OR UNRESPON? OR ((DO OR DOES OR IS)) "NOT" OR DONT OR ISNT OR DOESNT OR (DON OR ISN OR DOESN)) T OR NON) () (RESPOND? OR REACT? OR RESPONSIVE) OR (ZERO OR FAIL? OR NO OR NON) () (EFFECT? OR RESPON? ? OR RESULT?) OR NONEFFECT? OR NONRESULT?)
S4	133314	S (SECOND OR TWO OR NEXT OR SUBSEQUENT OR FOLLOWING OR FOLLOW()UP OR FOLLOWUP OR REPEAT OR ADDITIONAL) (2N) (ROUND? ? OR TRIAL? ? OR TEST??? OR PHASE? ? OR ADMINISTRATION? ? OR TREATMENT? ? OR EXPERIMENT? ?)
S5	13	S S1 AND S2
S6	0	S S2 AND S3
S7	44	S S3 AND S4
S8	2	S S7 AND S1
S9	35	S PLACEBO()EFFECT?
S10	7	S S9 AND S4
S11	0	S S9 AND S3
S12	6	S S9 AND S1
S13	79	S S12 OR S10 OR S9 OR S8 OR S7
S14	79	IDPAT S13 (sorted in duplicate/non-duplicate order)
S15	38	S S14 NOT PY>2003
S16	34	S S15 NOT (S8 OR S10)
S17	33	S S16 NOT S12
S18	0	S S9 AND S7

RESULTS: Patent Literature – Non Full Text Subject Search

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0011159516 & *Drawing available*

WPI Acc no: 2002-096909/200213

XRFX Acc No: N2002-071582

System for controlled study of effectiveness of medical electronic apparatus, has placebo device with high permeability ferromagnetic layer attached to magnet

Patent Assignee: HOLCOMB R R (HOLC-I)

Inventor: HOLCOMB R R

Patent Family (1 patents, 1 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20010041917	A1	20011115	US 2000174891	P	20000107	200213	B
			US 2001756474	A	20010108		

System for controlled study of effectiveness of medical electronic apparatus, has placebo device with high permeability ferromagnetic layer attached to magnet Original Publication Data by AuthorityArgentinaPublication No. Original Abstracts: A placebo device for controlled testing of an apparatus for treating pain with a combination magnetic and electric therapies features a multi-polar, three dimensional... Claims: 1. A system for the controlled study of the effectiveness of a medical electronic apparatus for treating pain by the application of an electrical stimulus...

5/3,K/2 (Item 2 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0014110077

WPI Acc no: 2004-294389/200427

Related WPI Acc No: 1999-508160; 2001-272995

XRAM Acc no: C2004-112595

Drug delivery regimen comprising doses of therapeutic agents, e.g. vitamin and mineral, administered during 24 hour period, in uneven doses and over variant time intervals to optimize levels of therapeutic agents at site of action

Patent Assignee: HERMELIN V M (HERM-I)

Inventor: HERMELIN V M

Patent Family (1 patents, 1 & countries)

Patent Number	Kind	Date	Application	Kind	Date	Update	Type
---------------	------	------	-------------	------	------	--------	------

			Number				
US 20040062802	A1	20040401	US 199853487	A	19980402	200427	B
			US 1999323158	A	19990601		
			US 1999475992	A	19991230		
			US 2003644041	A	20030820		

Extension Abstract ...International Prostate Symptom Score (I-PSS) and maximum urinary flow rate (Qmax), both measured at screening, after the 2 week placebo run-in period (baseline) and at 6, 12 and 24 weeks (end-point) subsequent to... Extension Abstract Image Original Publication Data by AuthorityArgentinaPublication No. ...Claims:of action for maximum efficacy, and wherein the dose amount at each administration is independently characterized by the formula $TD(t)=CD(t)+RD(t)$, where t is the time at which the dose...

5/3,K/1 (Item 1 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0014925328

WPI Acc no: 2005-273033/200528

XRAM Acc no: C2005-085318

XRPX Acc No: N2005-224367

Identifying a biological basis for a placebo effect comprises comparing at least a first biological marker of a first individual or population of individuals to the first biological marker for a second individual or population

Patent Assignee: PERLEGEN SCI INC (PERL-N)

Inventor: COX D; COX D A; HSU J; MARGUS B; MARGUS B A

Patent Family (3 patents, 106 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2005027719	A2	20050331	WO 2004US29921	A	20040913	200528	B
US 20050079532	A1	20050414	US 2003502864	P	20030912	200528	E
			US 2004940410	A	20040913		
US 7335474	B2	20080226	US 2003502864	P	20030912	200816	E
			US 2004940410	A	20040913		

Alerting Abstract ... a placebo effect; and determining whether the putative placebo effect-modulatory agent modulates the placebo effect in the individual; a system for identifying a biological basis for a placebo effect, the system comprising at least one biological marker data set corresponding to at least a first biological... first biological marker between the individuals and for correlating the first marker to the placebo effect; a system for correlating biological marker data to a biologically-encoded placebo effect, the system comprising at least one biological marker data set corresponding to at least one biological marker that correlates with at least one placebo effect; and computer-implemented system instructions comprising instructions for correlating the data set to the placebo effect; a system for

screening an individual or population for susceptibility to a placebo effect, the system comprising data corresponding to one or more test biological markers in a biological sample derived... .. determining whether the individuals comprise one or more test biological markers associated with the placebo effect; and a system for determining a placebo-normalized activity of a putative therapeutic agent, the system comprising activity... .. to population members of the first population that are biologically predisposed to display a placebo effect; and computer-implemented system instructions that provide a normalized data set by adding or subtracting values from the activity... Technology Focus ...that comprises system instructions that normalize one or more activity data sets for the placebo effect. The systems further comprise a user viewable display for viewing an output of the computer-implemented system... Extension Abstract

10/3,K/4 (Item 4 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0013304754 & *Drawing available*

WPI Acc no: 2003-391689/200337

XRAM Acc no: C2003-104029

XRPX Acc No: N2003-312869

Conducting pharmacological research studies involves exposing first and second sets of participants to different pharmacological treatment regimen, and exposing first and second groups to behavioral modification regimen

Patent Assignee: FLYNN P (FLYN-I); SCHAEFER M S (SCHA-I)

Inventor: FLYNN P; SCHAEFER M S

Patent Family (1 patents, 1 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20020188471	A1	20021212	US 2001287931	P	20010430	200337	B
			US 2002136740	A	20020430		

Priority Applications (no., kind, date): US 2001287931 P 20010430; US 2002136740 A 20020430

Patent Details

Patent Number	Kind	Lang	Pgs	Draw	Filing Notes	
US 20020188471	A1	EN	24	6	Related to Provisional	US 2001287931

Alerting Abstract ... medical condition; dividing the study participants into a first and a second set of participants; providing a pharmacological treatment regimen comprising a pharmacological component, exposing the first set of participants to the pharmacological treatment... .. component comprises a component selected for testing in the treatment of the predefined medical condition; exposing the second set of participants to the pharmacological

treatment regimen, where the pharmacological component comprises a second effect upon the medical condition; providing a behavioral modification regimen selected to treat behavioral components... Technology Focus INSTRUMENTATION AND TESTING - Preferred Component: The second effect on the medical condition is a placebo effect, having no pharmacological effect on the medical condition. The component selected for testing comprises a... Extension Abstract

10/3,K/5 (Item 5 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0012714926

WPI Acc no: 2002-566658/200260

XRAM Acc no: C2002-160623

Conducting clinical trials for assessment of individual patient's response to a drug or other medical procedure used to treat a condition of the patient

Patent Assignee: BECKER R (BECK-I); BECKER R E (BECK-I)

Inventor: BECKER R; BECKER R E

Patent Family (4 patents, 94 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2002051354	A2	20020704	WO 2001US49457	A	20011026	200260	B
US 20030088365	A1	20030508	WO 2001US49457	A	20011026	200337	E
			US 2002182785	A	20020801		
AU 2002239664	A1	20020708	AU 2002239664	A	20011026	200427	E
AU 2002239664	A8	20051013	AU 2002239664	A	20011026	200616	E

Technology Focus ...treatment conditions, statistically supporting the internal validity of the CT, selecting confidence intervals, and distinguishing two or more different clinical courses. Determining whether an individual patient's condition is improving or not includes using... measurement of outcomes from treatment, and using the confidence intervals to test for treatment and placebo effects in n-of-1 trials. Determining whether the measured improvement will result in a long-term favorable outcome for the patient includes generating probabilities for long-term outcomes specific to distinct clinical responses... Extension Abstract

10/3,K/2 (Item 2 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

001452461

WPI Acc no: 2005-172297/200511

Related WPI Acc No: 2005-57046

XR-AM Acc. no. C2005-05529

Non-continuous administration of pharmaceuticals for treating symptoms of menstrual cycle in female involves oral daily dosages of one of placebo and pharmaceutical starting on first day of cycle followed by the other starting on second day
 Patent Assignee: BOISSONNAT L R M (BOIS L); DEVRIES T M (DEVRE T); ELLMAN H (ELLM H); MACFARLANE K J (MACF J); SMITH K J (SMIT J)
 Invention: BOISSONNAT L R M; DEVRIES T M; ELLMAN H; MACFARLANE K J; SMITH K J

Patent Family (1 patents, 1 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
US 20050038005	A1	20050217	US 2003639891	A	20030812	200518	B
			US 2004762263	A	20040123		
			US 2004819764	A	20040407		

Priority Applications (no., kind, date): US 2003639891 A 20030812; US 2004762263 A 20040123; US 2004819764 A 20040407

Patent Details

Patent Number	Kind	Lan	Pgs	Draw	Filing Notes	
US 20050038005	A1	EN	13	8	C-I-P of application	US 2003639891
					C-I-P of application	US 2004762263

Alerting Abstract ... one of (F1) and (S1) is a placebo and the other is the pharmaceutical. During administration, either the second dosage period is a selected number of days to administer the pharmaceutical for the treatment and the first dosage period is determined by subtracting the... first dosage period is a selected number of days to administer the pharmaceutical for the treatment and the second dosage period is determined by subtracting the selected number of days from the number of days in the female's menstrual cycle, when (F1) is... Original Publication Data by AuthorityArgentinaPublication No. ...Original Abstracts:the second day of the menstrual cycle and continuing the daily administration for a first dosage period. Next administering a daily second dosage, starting on the day after the last daily first dosage was administered and continuing the daily administration of the second dosage for a second dosage period. Wherein either the first dosage is a placebo and the second dosage is... Claims:the day after the last daily first dosage was administered and continuing the daily oral administration of said second dosage for a second dosage period or until the onset of menses;wherein either (i) said first dosage is a placebo and said second dosage is said pharmaceutical, and said second dosage period is a selected number of days to administer said pharmaceutical for effective treatment of said condition and said first dosage period is determined by subtracting the selected number of days... said first dosage period is a selected number of days to administer said pharmaceutical for effective treatment of said condition and said second dosage period is determined by subtracting the selected...

Alerting Abstract ...ADVANTAGE - The system separates the placebo effect of brain diseases forming poly-double logarithmic reductions within the equivalence class.

12/3,K/3 (Item 3 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0014925328

WPI Acc no: 2005-273033/200528

XRAM Acc no: C2005-085318

XRPX Acc No: N2005-224367

Identifying a biological basis for a placebo effect comprises comparing at least a first biological marker of a first individual or population of individuals to the first biological marker for a second individual or population

Patent Assignee: PERLEGEN SCI INC (PERL-N)

Inventor: COX D; COX D A; HSU J; MARGUS B; MARGUS B A

Patent Family (3 patents, 106 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	UpDate	Type
WO 2005027719	A2	20050331	WO 2004US29921	A	20040913	200528	B
US 20050079532	A1	20050414	US 2003502864	P	20030912	200528	I
			US 2004940410	A	20040913		
US 7335474	B2	20080226	US 2003502864	P	20030912	200816	I
			US 2004940410	A	20040913		

Identifying a biological basis for a placebo effect comprises comparing at least a first biological marker of a first individual or population of... Original Titles:Methods and systems for identifying predisposition to the placebo effectMethods and systems for identifying predisposition to the placebo effectMETHODS AND SYSTEMS FOR IDENTIFYING PREDISPOSITION TO THE PLACEBO EFFECT Alerting Abstract ...NOVELTY - Identifying a biological basis for a placebo effect comprising comparing at least a first biological marker of a first individual or population of... DESCRIPTION - Identifying a biological basis for a placebo effect comprising comparing at least a first biological marker of a first individual or population of... .. or population of individuals; and correlating the at least a first biological marker to the placebo effect, thus identifying the biological basis for the placebo effect. screening an individual or population for susceptibility to a placebo effect by analyzing a biological sample derived from the individual or population, or data corresponding to... .. sample, for a presence or absence of one or more biological marker associated with the placebo effect, where a susceptibility to the placebo effect is determined; testing a placebo-normalized activity of a putative therapeutic agent by administering the... .. Extension Abstract Original Publication Data by AuthorityArgentinaPublication No. Original Abstracts:Methods and systems for identifying biological marker-placebo effect correlations are provided. Clinical trial design and data analysis of clinical trial data is modified to accommodate marker-placebo effect

correlations... .. Methods and systems for identifying biological marker-placebo effect correlations are provided. Clinical trial design and data analysis of clinical trial data is modified to accommodate marker-placebo effect correlations... .. Methods and systems for identifying biological marker-placebo effect correlations are provided. Clinical trial design and data analysis of clinical trial data is modified to accommodate marker-placebo effect correlations... Claims: What is claimed is: 1. A method of identifying a biological basis for a placebo effect, the method comprising: comparing at least a first biological marker of a first individual or... .. or population of individuals; and, correlating the at least a first biological marker to the placebo effect, thereby identifying the biological basis for the placebo effect....
... an association study to identify a correlation between one or more genetic markers and a placebo effect, the method comprising: determining a first frequency of the one or more markers for a... .. one or more markers in a second population, wherein the first population differentially exhibits the placebo effect as compared to the second population; and, comparing the first frequency and the second frequency... .. the second frequency indicates a correlation between the one or more genetic markers and the placebo effect.>

17/3,K/12 (Item 7 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0010987830

WPI Acc no: 2001-612611/200171

XRAM Acc no: C2001-183189

Active principle extracted from nasturtium used in cosmetic formulations for the depigmenting and lightening of the skin

Patent Assignee: SILAB SOC IND LIMOUSINE APPL BIOLOGIQUE (SILA-N)

Inventor: PAUFIQUE JJ

Patent Family (1 patents, 1 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
FR 2806623	A1	20010928	FR 20003718	A	20000323	200171	B

Priority Applications (no., kind, date): FR 20003718 A 20000323

Patent Details

Patent Number	Kind	Lan	Pgs	Draw	Filing Notes
FR 2806623	A1	FR	11	0	

Extension Abstract ...days to one hand of each of 15 testees which the other hand received a placebo. Effectiveness was measured chromatometrically taking values I. (intensity) and b (color). Averaged results were: Active principle ... Extension Abstract Image

17/3,K/15 (Item 10 from file: 350) [Links](#)

Fulltext available through: [Order File History](#)

Derwent WPIX

(c) 2008 Thomson Reuters. All rights reserved.

0010156125 & & *Drawing available*

WPI Acc no: 2000-464938/200040

XRPX Acc No: N2000-347026

Bio neutralizer transformer e.g. for protection of entire living world from electromagnetic radiation

Patent Assignee: VELKOSKI S (VELK-I)

Inventor: VELKOSKI S

Patent Family (2 patents, 87 & countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 2000025857	A1	20000511	WO 1999MK6	A	19991027	200040	B
AU 199964882	A	20000522	AU 199964882	A	19991027	200040	E

Alerting Abstract ...of radiation. Efficient which is measurable by existent apparatus in order to avoid manipulations with placebo effect.

Patent Literature Full Text – Subject Search

[File 348] EUROPEAN PATENTS 1978-200839

(c) 2008 European Patent Office. All rights reserved.

[File 349] PCT FULLTEXT 1979-2008/UB=20081002IUT=20080925

(c) 2008 WIPO/Thomson. All rights reserved.

Set	Items	Description
S1	323866	S (FORMULA? ? OR ALGORITHM? ? OR SYSTEM? ? OR METHODOLOGY OR FUNCTION? ? OR EQUATION? ? OR (STATISTIC? OR PROBABIL? OR MATHEMATIC?))METHOD? ?) (4N) (EFFECT? OR EFFICAC? OR USEFULNESS OR UTILITY OR RESPON???? OR RESULTS OR OUTCOME?)
S2	782	S (REDUC? OR DIMIN? OR MITIGAT? OR TAK?)ACCOUNT OR ELIMIN? OR (ALLOW? OR CONTROL?) (FOR OR BIAS? OR UNBIAS? OR SCREEN? OR FILTER?) (4N) (PLACEBO? OR (INACTIVE OR INERT OR FALSE OR DUMMY OR FAKE)) (SUBSTANCE OR DRUG OR TREATMENT OR PHARMACEUTICAL?) OR SUGAR()PILL? OR PSYCHOSOMATIC)
S3	3135	S (ELIMIN? OR DISQUAL? OR SCREEN? OR FILTER? OR REMOV? OR RID OR RIDDING OR DROP OR DROPS OR DROPP???) (4N) (NONRESPON? OR UNRESPON? OR (DO OR DOES OR IS)) "NOT" OR DONT OR ISNT OR DOESNT OR (DON OR ISN OR DOESN)) T OR NON)) (RESPOND? OR REACT? OR RESPONSIVE) OR (ZERO OR FAIL? OR NO OR NON)) (EFFECT? OR RESPON? ? OR RESULT?) OR NONEFFECT? OR NONRESULT?)
S4	266613	S (SECOND OR TWO OR NEXT OR SUBSEQUENT OR FOLLOWING OR FOLLOW()UP OR FOLLOWUP OR REPEAT OR ADDITIONAL) (2N) (ROUND? ? OR TRIAL? ? OR TEST??? OR PHASE? ? OR ADMINISTRATION? ? OR TREATMENT? ? OR EXPERIMENT? ?)
S5	323	S S1 AND S2
S6	7	S S3 AND S5
S7	9	S S3(5N)S4
S8	12	S S2(7N)S4
S9	582	S S1(3N)S4
S10	6	S S9 AND S2
S11	2	S S10 NOT (S6 OR S7 OR S8)

RESULTS: Patent Literature Full Text – Subject Search

6/3K/6 (Item 4 from file: 349) [Links](#)

Fulltext available through: [Order File History](#)

PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

00737652

GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE
TREATMENT OF DISEASE

VARIATIONS DE SEQUENCES GENIQUES PRESENTANT UNE UTILITE POUR LA
SELECTION DU TRAITEMENT D'UNE MALADIE

Patent Applicant/Patent Assignee:

- VARIAGENICS INC; 60 Hampshire Street, Cambridge, MA 02139-1562
US; US(Residence); US(Nationality)
(For all designated states except: US)
- STANTON Vincent Jr; 32 Royal Road, Belmont, MA 02173
US; US(Residence); US(Nationality)
(Designated only for: US)

Patent Applicant/Inventor:

- STANTON Vincent Jr
32 Royal Road, Belmont, MA 02173; US; US(Residence); US(Nationality); (Designated
only for: US)

Legal Representative:

- AMES Wesley B(agent)
Brobeck, Phleger & Harrison LLP, 12390 El Camino Real, San Diego, CA 92130; US;

	Country	Number	Kind	Date
Patent	WO	200050639	A2-A3	20000831
Application	WO	2000US1392		20000120
Priorities	US	99121047		19990222
	US	99139440		19990615
	US	99357743		19990720

Detailed Description:

...or suboptimal treatment.

....response trait can be tested. Alternatively, statistical methods that do not posit a specific genetic model... ...a clinical trial can be grouped (at the end of the trial) according to treatment response, and statistical methods can be used to compare allele (or genotype or

haplotype) frequencies in two groups. For... ..data can be treated as a continuous variable and the ability of genotype to predict response can be measured. In a preferred embodiments patients who exhibit extreme phenotypes are compared with... ..threshold for an outlier response' then the outlier response group should be almost free of placebo responders. This is a useful threshold because the inclusion of placebo responders in a 'true' response group decreases the ability of statistical methods to detect a genetic difference between responders and nonresponders.~~

8/3K/8 (Item 4 from file: 349) [Links](#)

Fulltext available through: [Order File History](#)

PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

01108590

ANALGESIC COMPOSITIONS COMPRISING NMDA RECEPTOR

ANTAGONISTS AND BENZALKONIUM CHLORIDE

COMPOSITIONS ANALGESIQUES A BASE D'ANTAGONISTES DU RECEPTEUR

NMDA ET CHLORURE DE BENZALKONIUM

Patent Applicant/Patent Assignee:

- INNOVATIVE DRUG DELIVERY SYSTEMS INC; 787 Seventh Avenue, New York, NY 10019
US; US(Residence); US(Nationality)

Legal Representative:

- LEE Sandra S(et al)(agent)
Darby & Darby, P.C., P.O. Box 5257, New York, NY 10150-5257; US;

	Country	Number	Kind	Date
Patent	WO	200428522	A1	20040408
Application	WO	2003US31073		20030925
Priorities	US	2002256283		20020925

Detailed Description:

...163 and 165 from Site 03. Patient 110 from Site 01 also attained a 40% reduction following treatment with placebo. This treatment 1 5 difference in ability to attain a greater than 40% reduction in...

8/3K/9 (Item 5 from file: 349) [Links](#)

Fulltext available through: [Order File History](#)

PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

00830463

METHOD OF TREATING AND DIAGNOSING SLEEP DISORDERED

BREATHING AND MEANS FOR CARRYING OUT THE METHOD
METHODE DE TRAITEMENT ET DE DIAGNOSTIC DE TROUBLES RESPIRATOIRES
DU SOMMEIL ET MOYEN DESTINE A LA MISE EN OEUVRE DE CETTE METHODE

Patent Applicant/Inventor:

- HEDNER Jan
Orangerigatan 4, S-412 66 Goteborg; SE; SE(Residence); SE(Nationality);
- GROTE Ludger
Viktoriagatan 34, S-411 25 Goteborg; SE; SE(Residence); DE(Nationality);
- SJOSTROM Lars
Ravstigen 1, S-436 55 Hovas; SE; SE(Residence); SE(Nationality);
- STENLOF Kaj
Hogenvagen 106, S-423 63 Torslanda; SE; SE(Residence); SE(Nationality);

Legal Representative:

- CONIMAR AB(agent)
Gerhard Miksche, Box 2086, S-141 02 Huddinge; SE;

	Country	Number	Kind	Date
Patent	WO	200162243	A1	20010830
Application	WO	2001SE315		20010214
Priorities	SE	2000601		20000224

Detailed Description:

...each cross-over period. A wash-out period of one week was applied between the two treatment periods.~~ A/H index during placebo (24 and 33) was reduced (to 9 and 6, respectively) during topiramate.

The most pronounced relative reduction was seen in...

8/3K/11 (Item 7 from file: 349) [Links](#)

Fulltext available through: [Order File History](#)

PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

00371478

METHOD FOR THE IDENTIFICATION AND THERAPEUTIC USE OF DISEASE-
ASSOCIATED ORGANISMS, ELEMENTS AND FORCES
PROCEDE D'IDENTIFICATION ET D'UTILISATION THERAPEUTIQUE
D'ORGANISMES, D'ELEMENTS ET DE FORCES ASSOCIES A UNE MALADIE

Patent Applicant/Patent Assignee:

- CHACHOUA Samir;
;;

	Country	Number	Kind	Date
Patent	WO	9712220	A2	19970403
Application	WO	96IB1006		19960913
Priorities	US	953686		19950915

Non Patent Literature Non Full Text Subject Search

[File 35] Dissertation Abs Online 1861-2008/Sep

(c) 2008 ProQuest Info&Learning. All rights reserved.

**File 35: UD names adjusted; All data present.*

[File 583] Gale Group Globalbase(TM) 1986-2002/Dec 13

(c) 2002 Gale/Cengage. All rights reserved.

**File 583: This file is no longer updating as of 12-13-2002.*

[File 65] Inside Conferences 1993-2008/Oct 03

(c) 2008 BLDSC all rts. reserv. All rights reserved.

[File 2] INSPEC 1898-2008/Sep W1

(c) 2008 Institution of Electrical Engineers. All rights reserved.

[File 474] New York Times Abs 1969-2008/Oct 04

(c) 2008 The New York Times. All rights reserved.

[File 475] Wall Street Journal Abs 1973-2008/Oct 06

(c) 2008 The New York Times. All rights reserved.

[File 99] Wilson Appl. Sci & Tech Abs 1983-2008/Aug

(c) 2008 The HW Wilson Co. All rights reserved.

[File 5] Biosis Previews(R) 1926-2008/Sep W4

(c) 2008 The Thomson Corporation. All rights reserved.

[File 73] EMBASE 1974-2008/Oct 03

(c) 2008 Elsevier B.V. All rights reserved.

[File 155] MEDLINE(R) 1950-2008/Oct 03

(c) format only 2008 Dialog. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2008/Oct W1

(c) 2008 The Thomson Corp. All rights reserved.

[File 434] SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp. All rights reserved.

[File 74] Int.Pharm.Abs 1970-2008/Aug B1

(c) 2008 The Thomson Corporation. All rights reserved.

[File 42] Pharm. News Index 1974-2008/Sep W1

(c) 2008 ProQuest Info&Learning. All rights reserved.

Set	Items	Description
S1	1649599	S (FORMULA? ? OR ALGORITHM? ? OR SYSTEM? ? OR METHODOLOGY OR FUNCTION? ? OR EQUATION? ? OR (STATISTIC? OR PROBABIL? OR MATHEMATIC?)) (METHOD? ?) (4N) (EFFECT? OR EFFICAC? OR USEFULNESS OR UTILITY OR RESPON???? OR RESULTS OR OUTCOME?)

S2 16759 S (REDUC? OR DIMIN? OR MITIGAT? OR TAK?())ACCOUNT OR
 ELIMIN? OR (ALLOW? OR CONTROL?())FOR OR BIAS? OR UNBIAS? OR SCREEN? OR
 FILTER?)(4N)(PLACEBO? OR (INACTIVE OR INERT OR FALSE OR DUMMY OR
 FAKE)())(SUBSTANCE OR DRUG OR TREATMENT OR PHARMACEUTICAL?) OR
 SUGAR()PILL? OR PSYCHOSOMATIC)
 S3 4414 S (ELIMIN? OR DISQUAL? OR SCREEN? OR FILTER? OR REMOV?
 OR RID OR RIDDING OR DROP OR DROPS OR DROPP???) (4N) (NONRESPON? OR
 UNRESPON? OR ((DO OR DOES OR IS)()) "NOT" OR DONT OR ISNT OR DOESNT OR
 (DON OR ISN OR DOESN)())T OR NON)()(RESPOND? OR REACT? OR RESPONSIVE) OR
 (ZERO OR FAIL? OR NO OR NON)()(EFFECT? OR RESPON? ? OR RESULT?) OR
 NONEFFECT? OR NONRESULT?)
 S4 1544820 S (SECOND OR TWO OR NEXT OR SUBSEQUENT OR FOLLOWING OR
 FOLLOW()UP OR FOLLOWUP OR REPEAT OR ADDITIONAL) (2N) (ROUND? ? OR TRIAL?
 ? OR TEST??? OR PHASE? ? OR ADMINISTRATION? ? OR TREATMENT? OR
 EXPERIMENT?)
 S5 29 S S1(7N)S2
 S6 24 S S5 NOT PY>2003
 S7 119 S S1 AND S2 AND S4
 S8 4 S S7 AND ((TREATMENT OR ADMINISTRATION OR ADMINISTER?
)(2N) (ACTIVE OR REAL OR TRUE OR ACTUAL OR NON())PLACEBO OR NONPLACEBO))
 S9 19 S S3(4N)S4
 S10 19 S S9 NOT (S8 OR S6)
 S11 8 RD (unique items)
 S12 6 S S11 NOT PY>2003
 S13 0 S S2 AND S3

RESULTS: Non Patent Literature Non Full Text Subject Search

6/3,K/22 (Item 4 from file: 34) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

05994500 Genuine Article#: XM773 No. References: 26

Classical conditioning and the placebo effect

Author: Montgomery GH; Kirsch I (REPRINT)

Corporate Source: UNIV CONNECTICUT,DEPT PSYCHOL, U20, 406 BABBIDGE RD/STORRS//CT/06269 (REPRINT); UNIV CONNECTICUT,DEPT PSYCHOL, U20/STORRS//CT/06269

Journal: PAIN , 1997 , V 72 , N1-2 (AUG) , P 107-113

ISSN: 0304-3959 Publication date: 19970800

Publisher: ELSEVIER SCIENCE BV , PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Abstract: ...placebo expectancies during conditioning trials and by assessing placebo expectancies. Although conditioning trials significantly enhanced placebo responding, this effect was eliminated by adding expectancies to the regression equation, indicating that the effect of pairing trials on placebo response was mediated completely by expectancy. Verbal information reversed the...

Identifiers--

6/3,K/13 (Item 3 from file: 155) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

MEDLINE(R)

(c) format only 2008 Dialog. All rights reserved.

13296588 PMID: 10537458

Using CQI to prevent the placebo effect from causing failed clinical trials.

Fawcett J; Sinioris M E

Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.

Quality management in health care (UNITED STATES) Spring 1999 , 7 (3) p1-6 , ISSN: 1063-8628--Print Journal Code: 9306156

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

...in drug development is that most patients' responses are enhanced or affected by the "placebo effect." An ongoing methodology for reducing the impact of placebo effect should be built into the clinical study design at the outset based on a... ~~~

8/3,K/4 (Item 1 from file: 34) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

SciSearch(R) Cited Ref Sci

(c) 2008 The Thomson Corp. All rights reserved.

10965782 Genuine Article#: 589NG No. References: 9

The SCOPE trial

Author: Sever P (REPRINT)

Corporate Source: Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Clin Pharmacol, NHI Div, QEOM Wing/London W2 1NY//England/ (REPRINT); Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Clin Pharmacol, NHI Div, London W2 1NY//England/

Journal: JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, V 3, N2 (JUN), P 61-62

ISSN: 1470-3203 Publication date: 20020600

Publisher: J R A S LTD, EDGBASTON HOUSE, 3 DUCHESS PLACE, EDGBASTON, BIRMINGHAM B16 8NH, ENGLAND

Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)

Abstract: ...cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke was not significantly reduced by active treatment (relative risk reduction 11%, p=0.19).

There was also no significant difference in the decline of cognitive function between the two treatment arms.

Active treatment of the placebo group (mainly hydrochlorothiazide) reduced the blood pressure differences between the treatment arms to only 3.2/1.6 mmHg...

Identifiers--

8/3,K/3 (Item 3 from file: 73) [Links](#)

Fulltext available through: [STIC Full Text Retrieval Options](#)

EMBASE

(c) 2008 Elsevier B.V. All rights reserved.

0078819924 EMBASE No: 2001426335

The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials

Faries D.E.; Heiligenstein J.H.; Tollefson G.D.; Potter W.Z.

Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, United States

Corresp. Author/Affil: Faries D.E.; Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, United States

Corresp. Author Email: d.faries@lilly.com

Journal of Clinical Psychopharmacology (J. Clin. Psychopharmacol.) (United States)

December 18, 2001, 21/6 (561-568)

CODEN: JCPYD ISSN: 0271-0749

Item Identifier (DOI): [10.1097/00004714-200112000-00004](#)

Document Type: Journal; Article Record Type: Abstract

Language: English Summary language: English

Number of References: 11

The double-blind variable placebo lead-in period: Results from two antidepressant clinical trials

...blind placebo lead-in did not decrease postrandomization placebo response, nor did it increase drug-placebo differences. To eliminate a higher percentage of placebo responders before randomization and to reduce potential biases in baseline ratings, the authors designed and... ..blinded to the length of the placebo lead-in period and the start of the active treatment period. Approximately 28% of the patients in the double-blind placebo lead-in studies met...

Medical Descriptors:

*

article; clinical trial; disease severity; drug response; human; methodology; performance; priority journal; randomization; sampling; single blind procedure
Orig. Descriptors:

NonPatent Literature Full Text Subject Search

[File 149] TGG Health&Wellness DB(SM) 1976-2008/Sep W1

(c) 2008 Gale/Cengage. All rights reserved.

[File 444] New England Journal of Med. 1985-2008/Jun W5

(c) 2008 Mass. Med. Soc. All rights reserved.

[File 455] Drug News & Perspectives 1992-2005/Aug

(c) 2005 Prous Science. All rights reserved.

**File 455: This file is closed. Please see HELP NEWS 455 for more information.*

[File 129] PHIND(Archival) 1980-2008/Sep W4

(c) 2008 Informa UK Ltd. All rights reserved.

[File 130] PHIND(Daily & Current) 2008/Oct 02

(c) 2008 Informa UK Ltd. All rights reserved.

[File 15] ABI/Inform(R) 1971-2008/Oct 06

(c) 2008 ProQuest Info&Learning. All rights reserved.

[File 9] Business & Industry(R) Jul/1994-2008/Sep 26

(c) 2008 Gale/Cengage. All rights reserved.

[File 610] Business Wire 1999-2008/Oct 06

(c) 2008 Business Wire. All rights reserved.

**File 610: File 610 now contains data from 3/99 forward. Archive data (1986-2/99) is available in File 810.*

[File 810] Business Wire 1986-1999/Feb 28

(c) 1999 Business Wire . All rights reserved.

[File 275] Gale Group Computer DB(TM) 1983-2008/Sep 23

(c) 2008 Gale/Cengage. All rights reserved.

[File 995] NewsRoom 2004

(c) 2008 Dialog. All rights reserved.

[File 996] NewsRoom 2000-2003

(c) 2008 Dialog. All rights reserved.

[File 624] McGraw-Hill Publications 1985-2008/Oct 06

(c) 2008 McGraw-Hill Co. Inc. All rights reserved.

**File 624: Journal updates now current*

[File 621] Gale Group New Prod.Annou.(R) 1985-2008/Sep 12

(c) 2008 Gale/Cengage. All rights reserved.

[File 636] Gale Group Newsletter DB(TM) 1987-2008/Sep 25

(c) 2008 Gale/Cengage. All rights reserved.

[File 613] PR Newswire 1999-2008/Oct 06

(c) 2008 PR Newswire Association Inc. All rights reserved.

**File 613: File 613 now contains data from 5/99 forward. Archive data (1987-4/99) is available in File 813.*

[File 813] PR Newswire 1987-1999/Apr 30

(c) 1999 PR Newswire Association Inc. All rights reserved.

[File 16] Gale Group PROMT(R) 1990-2008/Sep 25

(c) 2008 Gale/Cengage. All rights reserved.

**File 16: Because of updating irregularities, the banner and the update (UD=) may vary.*

[File 160] Gale Group PROMT(R) 1972-1989

(c) 1999 The Gale Group. All rights reserved.

[File 634] San Jose Mercury Jun 1985-2008/Sep 30

(c) 2008 San Jose Mercury News. All rights reserved.

[File 148] Gale Group Trade & Industry DB 1976-2008/Oct 02

(c) 2008 Gale/Cengage. All rights reserved.

**File 148: The CURRENT feature is not working in File 148. See HELP NEWS148.*

[File 20] Dialog Global Reporter 1997-2008/Oct 06

(c) 2008 Dialog. All rights reserved.

Set	Items	Description
S1	1370756	S (FORMULA? ? OR ALGORITHM? ? OR SYSTEM? ? OR METHODOLOGY OR FUNCTION? ? OR EQUATION? ? OR (STATISTIC? OR PROBABIL? OR MATHEMATIC?) (METHOD? ?) (4N) (EFFECT? OR EFFICAC? OR USEFULNESS OR UTILITY OR RESPON???? OR RESULTS OR OUTCOME?)
S2	13986	S (REDUC? OR DIMIN? OR MITIGAT? OR TAK?()) ACCOUNT OR ELIMIN? OR (ALLOW? OR CONTROL?) (FOR OR BIAS? OR UNBIAS? OR SCREEN? OR FILTER?) (4N) (PLACEBO? OR (INACTIVE OR INERT OR FALSE OR DUMMY OR FAKE) (SUBSTANCE OR DRUG OR TREATMENT OR PHARMACEUTICAL?) OR SUGAR() PILL? OR PSYCHOSOMATIC)
S3	3170	S (ELIMIN? OR DISQUAL? OR SCREEN? OR FILTER? OR REMOV? OR RID OR RIDDING OR DROP OR DROPS OR DROPP???) (4N) (NONRESPON? OR UNRESPON? OR (DO OR DOES OR IS) () "NOT" OR DONT OR ISNT OR DOESNT OR (DON OR ISN OR DOESN) (T OR NON) () (RESPOND? OR REACT? OR RESPONSIVE) OR (ZERO OR FAIL? OR NO OR NON) () (EFFECT? OR RESPON? ? OR RESULT?) OR NONEFFECT? OR NONRESULT?)
S4	3582596	S (SECOND OR TWO OR NEXT OR SUBSEQUENT OR FOLLOWING OR FOLLOW() UP OR FOLLOWUP OR REPEAT OR ADDITIONAL) (2N) (ROUND? ? OR TRIAL? ? OR TEST??? OR PHASE? ? OR ADMINISTRATION? ? OR TREATMENT? OR EXPERIMENT?)
S5	6	S S1(3N) S2
S6	2	S S2(3N) S3
S7	8	S S3(4N) S4
S8	8	S S7 NOT (S5 OR S6)
S9	91	S S2(4N) S4
S10	0	S S9 AND S3
S11	0	S S9 AND (PLACEBO() EFFECT?)
S12	1	S S9 AND ((TREATMENT OR ADMINISTRATION OR ADMINISTER?) (2N) (ACTIVE OR REAL OR TRUE OR ACTUAL OR NON() PLACEBO OR NONPLACEBO))

S13	1345	S S1(4N)S4
S14	9	S S13 AND S2
S15	9	S S14 NOT (S12 OR S5 OR S6)
S16	20	S S3 AND ((TREATMENT OR ADMINISTRATION OR ADMINISTER?
)(2N) (ACTIVE OR REAL OR TRUE OR ACTUAL OR NON()PLACEBO OR NONPLACEBO))

RESULTS NonPatent Literature Full Text Subject Search

5/3,K/5 (Item 1 from file: 996) [Links](#)

NewsRoom 2000-2003

(c) 2008 Dialog. All rights reserved.

0150006476 157E06AC

St Jude begins clinical trial of new therapy for heart failure patients

MEDICAL INDUSTRY WEEK

Monday , October 16, 2000

Journal Code: AJWC Language: ENGLISH Record Type: Fulltext

Document Type: Trade Journal ISSN: 1462-8716

Word Count: 433

Text:

...six months. Both arms of the study will receive the Genesis system in order to mitigate a potential placebo effect. Utilising the Genesis system, St Jude is involved in several other clinical trials to evaluate the efficacy of left...

6/3,K/2 (Item 2 from file: 149) [Links](#)

TGG Health&Wellness DB(SM)

01766220 Supplier Number: 20565426 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Methodological issues in treatment research for anxiety disorders in youth.

Kendall, Philip C.; Flannery-Schroeder, Ellen C.

Journal of Abnormal Child Psychology , v26 , n1 , p27(12)

Feb ,

1998

Publication Format: Magazine/Journal; Refereed

ISSN: 0091-0627

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic; Professional

Word Count: 9029 Line Count: 00790

...disorders (see Allen et al, 1995).

A practice that is used in some pharmacotherapy research - eliminating placebo responders or drug nonresponders from the trial - can produce an unfair and biased evaluation of medication effects. The practice...~

8/3,K/8 (Item 2 from file: 148) [Links](#)

Gale Group Trade & Industry DB

(c) 2008 Gale/Cengage. All rights reserved.

05117586 Supplier Number: 10477323 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Stripper well production increases with MEOR treatment. (stimulation of oil wells productivity by microbial injection)

Nelson, Sidney J.; Launt, Phillip D.

Oil and Gas Journal, v89, n11, p114(4)

March 18, 1991

ISSN: 0030-1388

Language: ENGLISH

Record Type: FULLTEXT

Word Count: 2519 Line Count: 00218

...the pattern of response is developed for those wells showing a positive response. Wells that do not respond after two treatments are dropped from the program and new candidates sought.

16/3,K/6 (Item 6 from file: 149) [Links](#)

TGG Health&Wellness DB(SM)

(c) 2008 Gale/Cengage. All rights reserved.

01766220 Supplier Number: 20565426 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Methodological issues in treatment research for anxiety disorders in youth.

Kendall, Philip C.; Flannery-Schroeder, Ellen C.

Journal of Abnormal Child Psychology, v26, n1, p27(12)

Feb,

1998

Publication Format: Magazine/Journal; Refereed

ISSN: 0091-0627

Language: English

Record Type: Fulltext; Abstract Target Audience: Academic; Professional

Word Count: 9029 Line Count: 00790

...disorders (see Allen et al, 1995).

A practice that is used in some pharmacotherapy research - eliminating placebo responders or drug nonresponders from the trial - can produce an unfair and biased evaluation of medication effects. The practice would be comparable to the removal of clients

who are nonresponsive to the psychosocial treatment.~~

Potential Ameliorative Strategies. Investigations of psychosocial treatments can include the use...

...use random assignments (see Hollon & DeRubeis, 1991). The absence of any "washout," "screening," or subject removal practices to eliminate nonresponders maintains the clinical trial as random. Other practices suspend randomization and undermine meaningful comparison.

ASSESSMENT...comparison of change across treatment to change across a waitlist period will help to distinguish true treatment efficacy from regression to the mean.

If it is possible for noncompleting participants to be...

16/3,K/18 (Item 3 from file: 148) [Links](#)

Gale Group Trade & Industry DB

(c) 2008 Gale/Cengage. All rights reserved.

15526201 Supplier Number: 95105502 (USE FORMAT 7 OR 9 FOR FULL TEXT)

The effects of primary care depression treatment on patients' clinical status and employment.

Schoenbaum, Michael; Unutzer, Jurgen; McCaffrey, Daniel; Duan, Naihua; Sherbourne, Cathy; Wells, Kenneth B.

Health Services Research, 37, 5, 1145(14)

Oct, 2002

ISSN: 0017-9124

Language: English

Record Type: Fulltext; Abstract

Word Count: 5079 Line Count: 00487

...results unadjusted for cluster effects. We weighted the data for the probability of selection at screening and for nonresponse at follow-up. We used multiple imputation ...these assumptions are violated, the estimated treatment effectiveness may be higher or lower than the true effect.

The treatment effectiveness we report could reflect not just the effects of appropriate treatment per se (i...

